Cellectar Biosciences Targets 2027 EU Launch for Iopofosine I 131

Cellectar Biosciences (NASDAQ: CLRB) has concluded a pivotal fiscal year 2025, positioning itself at the threshold of commercial-stage operations. The company’s strategic focus on its lead radiotherapeutic candidate, iopofosine I 131, has transitioned from early-stage clinical validation to a structured regulatory pathway, with a clear target for European market entry by 2027. This shift reflects a broader trend in the oncology sector, where specialized radiopharmaceuticals are gaining traction as highly targeted alternatives to traditional chemotherapy and immunotherapy.

The core of Cellectar’s value proposition lies in its proprietary Phospholipid Drug Conjugate (PDC) platform. Unlike traditional antibody-drug conjugates (ADCs), which can be limited by the expression of specific surface antigens, PDCs leverage the unique metabolic needs of malignant cells to deliver payloads—in this case, the radioisotope iodine-131—directly into the tumor microenvironment. This mechanism of action is particularly relevant for Waldenström Macroglobulinemia (WM), a rare and slow-growing form of non-Hodgkin lymphoma that often becomes resistant to existing therapies. By targeting the phospholipid ethers that are overexpressed in cancer cells, iopofosine I 131 aims to provide a more precise and less toxic treatment option for patients with limited remaining choices.

“

Cellectar Biosciences (NASDAQ: CLRB) has concluded a pivotal fiscal year 2025, positioning itself at the threshold of commercial-stage operations.

Regulatory progress remains the primary catalyst for Cellectar in the near term. The company confirmed it is on track to submit a Conditional Marketing Authorization (CMA) to the European Medicines Agency (EMA) in the third quarter of 2026. This pathway is critical for orphan indications like WM, where there is a high unmet medical need. A successful submission would pave the way for a potential commercial launch in the European Union by 2027. Management has also indicated ongoing productive dialogue with the U.S. Food and Drug Administration (FDA), suggesting that a domestic regulatory filing will likely follow the European timeline, though specific dates for a New Drug Application (NDA) were not explicitly detailed in the 2025 year-end update.

While iopofosine I 131 is the flagship asset, Cellectar is also diversifying its pipeline to mitigate single-asset risk and expand the utility of its PDC platform. The initiation of a Phase 1b dose-finding study for CLR 125 in triple-negative breast cancer (TNBC) marks a significant expansion into solid tumors. TNBC is notoriously difficult to treat due to its lack of estrogen, progesterone, and HER2 receptors, making it an ideal candidate for the receptor-independent targeting offered by the PDC technology. Early data from this study is expected by mid-year 2026, providing a critical secondary inflection point for investors and clinical partners.